185.62
+3.31(+1.82%)
Currency In USD
Address
1 North Waukegan Road
North Chicago, IL 60064-6400
United States of America
Phone
847 932 7900
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
55000
First IPO Date
January 02, 2013
Name | Title | Pay | Year Born |
Mr. Robert A. Michael CPA | Chief Executive Officer & Director | 6.68M | 1970 |
Mr. Scott T. Reents | Executive Vice President & Chief Financial Officer | 3.82M | 1968 |
Mr. Timothy J. Richmond | Executive Vice President & Chief Human Resources Officer | 3.84M | 1966 |
Dr. Azita Saleki-Gerhardt Ph.D. | Executive Vice President & Chief Operating Officer | 4.07M | 1963 |
Mr. Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer | 5M | 1969 |
Mr. Richard A. Gonzalez | Executive Chairman | 8.06M | 1954 |
Ms. Elizabeth Shea | Senior Vice President of Investor Relations | 0 | N/A |
Mr. Wulff-Erik von Borcke | Senior Vice President & President of Oncology | 0 | N/A |
Dr. Roopal Thakkar M.D. | Executive Vice President of Research and Development & Chief Scientific Officer | 0 | 1973 |
Mr. Perry C. Siatis | Executive Vice President, General Counsel & Secretary | 0 | 1976 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.